A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ACEIs / ACE inhibitors

[Related PubMed/MEDLINE]
Total Number of Papers: 79
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ACEIs  (>> Co-occurring Abbreviation)
Long Form:   ACE inhibitors
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 ACE inhibitor use and risk of cataract: a case-control analysis. CPRD
2019 Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction. ARBs, MI
2019 Do doctors in dispensing practices with a financial conflict of interest prescribe more expensive drugs? A cross-sectional analysis of English primary care prescribing data. ARBs, PPIs
2019 Impacts of person-centred integrated chronic heart failure and palliative home care on pharmacological heart failure treatment: a substudy of a randomised trial. BBs, CHF, MRAs, PREFER
2018 Effects of the concomitant administration of xanthine oxidase inhibitors with zofenopril or other ACE-inhibitors in post-myocardial infarction patients: a meta-analysis of individual data of four randomized, double-blind, prospective studies. AMI, XOIs
2018 In-hospital prescriptions of secondary-prevention medications for post-acute coronary syndrome patients in South Korea
. ACS, ARBs
2018 Microglial Activation Is Modulated by Captopril: in Vitro and in Vivo Studies. ACE, AD, Ang II, CAP, IL-10, iNOS, LPS, NO, RAS, TNF-alpha
2018 Mortality Reduction Associated With beta-Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes. beta-blockers, CHF
2018 Renin-angiotensin-aldosterone blockade reduces atrial fibrillation in hypertrophic cardiomyopathy. AF, ARBs, HCM, RAAS
10  2017 Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. ARBs, CV
11  2017 Kallikrein-kinin system as the dominant mechanism to counteract hyperactive renin-angiotensin system. ACE, Ang II, CVDs, KKS, RAS
12  2017 Relationship of quadriceps muscle power and optimal shortening velocity with angiotensin-converting enzyme activity in older women. ACE, ASBMs, PA, Pmax
13  2017 Use of ACE-inhibitors and falls in patients with Parkinson's disease. ARBs, PD
14  2017 Variation in hospital performance for heart failure management in the National Heart Failure Audit for England and Wales. ARBs, HFrEF, KPMs
15  2016 ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis. ARBs, CV, DM, HF, MI, RCTs
16  2016 Angiotensin Converting Enzyme Inhibitors Ameliorate Brain Inflammation Associated with Microglial Activation: Possible Implications for Alzheimer's Disease. ACE, AD, Ang II, iNOS, LPS, NO, RAS, TNF-alpha
17  2016 Combined statin and angiotensin-converting enzyme (ACE) inhibitor treatment increases the lifespan of long-lived F1 male mice. ACE, AT1R
18  2016 Inequity of access to ACE inhibitors in Swedish heart failure patients: a register-based study. HF
19  2016 Kinins and peptide receptors. AT1-R, B2R, CVDs, EDHF, KKS, NO, RAS
20  2016 Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. ARB
21  2015 Clinically important drug-drug interactions in poly-treated elderly outpatients: a campaign to improve appropriateness in general practice. ASA, DDIs, GPs, NSAIDs, SSRIs
22  2015 Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. ACE2
23  2015 Preadmission use of ACE inhibitors or angiotensin receptor blockers and short-term mortality after stroke. ARBs, ICH, MRRs, SAH
24  2014 Effects of treatment with zofenopril in men and women with acute myocardial infarction: gender analysis of the SMILE Program. AMI
25  2013 Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. ---
26  2013 Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. ARBs, DSS, OS, pCR, RFS
27  2012 Antioxidant therapies for the management of atrial fibrillation. AF, ARBs
28  2012 Impact of kinins in the treatment of cardiovascular diseases. ARBs, AT1-RAs, RAS
29  2012 Modeling of angiotensin II-angiotensin-(1-7) counterbalance in disease progression in spontaneously hypertensive rats treated with/without perindopril. Ang II, ELISA, RAS, SBP, SHR
30  2012 Prescription Pattern of Antihypertensive Agents in T2DM Patients Visiting Tertiary Care Centre in North India. ARBs, CCBs
31  2011 Evidence-based chronic heart-failure management programmes: reality or myth? CHF, CHF-MPs
32  2010 A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. ARBs, KIM-1, UAE
33  2010 Relation of the first hypertension-associated event with medication, compliance and persistence in naive hypertensive patients after initiating monotherapy. aHR, ARBs, BBs, CCBs
34  2010 Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. ARBs, RAAS
35  2010 The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan. Ang, ARB, BP, RAAS
36  2009 Perindopril: do randomised, controlled trials support an ACE inhibitor class effect? A meta-analysis of clinical trials. ---
37  2009 Telmisartan prevents cardiovascular events in a broad group of at-risk patients. ARBs
38  2008 Impact of disease management on utilization and adherence with drugs and tests: the case of diabetes treatment in the Florida: a Healthy State (FAHS) program. ARBs, FAHS
39  2008 NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans. ARBs, COX
40  2008 Predictors of cognitive decline in older individuals with diabetes. ACR, ARBs, CDR
41  2007 Antihypertensive drugs and the sympathetic nervous system. CCBs, SNS
42  2007 Do ACE Inhibitors/Angiotensin II type 1 receptor antagonists reduce hospitalisations in older patients with heart failure? A propensity analysis. AOR, ARBs, HF
43  2007 Scleroderma renal crisis: patient characteristics and long-term outcomes. SRC
44  2007 The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus. CCB, GPRD
45  2007 The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. ACE, Ang, ARBs, RAAS
46  2006 Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers. ACE, Ang II, ARBs, CVD, RAAS
47  2006 Impact of Modified System of Objectified Judgement Analysis (SOJA) methodology on prescribing costs of ACE inhibitors. SOJA
48  2006 New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. ACE-Is, ARBs, BHS, BP, CCBs, NICE
49  2006 The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy. ESRD
50  2006 Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease. ACE, AMI, SMILE
51  2006 Use of valsartan in post-myocardial infarction and heart failure patients. ACE, Ang II, ARBs, HF, LV, MI, RAAS
52  2006 [Aldosterone-to-renin ratio threshold for screening primary aldosteronism in Chinese hypertensive patients]. ARBs, ARR, CCBs
53  2005 Angiotensin II receptor blockade and ventricular remodelling. ACE, Ang II, ARBs, AT1, AT2, LV, RAAS
54  2005 Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. PET, PS, UF
55  2005 Is it the agent or the blood pressure level that matters for renal and vascular protection in chronic nephropathies? ARBs, CCBs, CKD
56  2005 Patient satisfaction with antihypertensive therapy. ARBs, BBs, BP, CCBs
57  2005 Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. ---
58  2004 Angiotensin inhibition in heart failure. ACE, ARB, LVEF, RAAS
59  2004 Arterial stiffness and the renin-angiotensin-aldosterone system. ACE, Ang II, ARBs, BP, RAAS
60  2004 Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction. ACE, BP, LV, MI
61  2004 The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era. ACE, LV, MI, PCI
62  2003 ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients? ACE, Ang II, ARBs, LIFE
63  2003 ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. MCP-1, uMCP-1
64  2003 Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold? ACE, ARBs, BP, MI, RAAS
65  2003 Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. ACE, Ang, HF, LV
66  2003 Identification and management of diabetic nephropathy in the diabetes clinic. AIIR
67  2003 Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs. BP, CCBs
68  2003 Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker. BK, OMA
69  2002 Long-term combined therapy with an angiotensin type I receptor blocker and an angiotensin converting enzyme inhibitor prolongs survival in dilated cardiomyopathy. RAS
70  2002 Novel peptidomimics as angiotensin-converting enzyme inhibitors: a combinatorial approach. ACE
71  2002 The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease. ACE, ARBs, ESRD
72  2001 ACE inhibitors and appearance of renal events in hypertensive nephrosclerosis. ---
73  2001 Differential subcellular actions of ACE inhibitors and AT(1) receptor antagonists on cardiac remodeling induced by chronic inhibition of NO synthesis in rats. ARBs, ERK, L-NAME, LVW/BW, SBP
74  2000 Collaborative partnership for optimizing heart failure outcomes in the long-term care environment: a clinical experience. HF, HF-HOMP
75  2000 Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. ACE, LVH, LVMI, PCR, RT
76  2000 Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. ---
77  2000 [The effects of enalapril on exercise capacity and right ventricular function in patients with chronic cor pulmonale]. COPD, RV
78  1998 Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles. ACE
79  1992 The clinical pharmacology of angiotensin converting enzyme inhibitors in chronic heart failure. ---